Health Care

Jasper Therapeutics insider buys options & preferred stock amid Kira merger, signaling confidence and potential upside for long‑term investors.

CEO’s large stock‑option buys at Cingulate signal confidence in the FDA‑approved neurodegenerative drug CTx‑1301, a potential market‑shifting breakthrough.

Insider buy of 26,655 OMADA Health shares signals board confidence, as clinical trials show 5‑7% weight loss and 0.6‑0.8% HbA1c reduction with safe, FDA‑supported digital care.

Guardant Health insider buying by Hidalgo Medina shows confidence amid volatile prices and a BBB credit upgrade—what this means for investors.

Insider selling spikes at Cerus Corp reveal the CEO’s strategy amid a 121% year‑to‑date gain and a high‑risk biotech focus on pathogen‑inactivation technology.

Coen Steven P. buys Ginkgo Bioworks shares amid a steep decline, signaling insider confidence in the synthetic‑biology firm’s future upside.

Insider buying at Greenland Mines signals confidence in its upgraded Skaergaard project, offering a rare insight into high‑risk exploration and parallels to biotech drug development.

MoonLake insider sales show routine portfolio rebalancing, not panic—CSO Reich Kristian sells 16k shares at $20.01 amid a 63% stock drop.

Explore what MAPLIGHT Therapeutics’ bulk insider selling means for investors—tax‑cover moves, pipeline outlook, and market impact explained.

Insider sale of 10 Lyell Immunopharma shares by Innovative Cellular Therapeutics shows routine liquidity, not a shift in long‑term confidence.